T. Rowe Price Associates
IMVT icon

T. Rowe Price Associates’s Immunovant IMVT Stock Holding History

T. Rowe Price Associates’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.5M Buy
1,829,210
+1,489,603
+439% +$45.4M 0.01% 787
2026
Q1 		$8.44M Sell
339,607
-553,449
-62% -$14.3M ﹤0.01% 1252
2025
Q4 		$22.7M Buy
893,056
+688,472
+337% +$15.4M ﹤0.01% 1038
2025
Q3 		$3.3M Buy
204,584
+143,470
+235% +$2.32M ﹤0.01% 1536
2025
Q2 		$978K Sell
61,114
-683,430
-92% -$10.3M ﹤0.01% 1999
2025
Q1 		$12.7M Sell
744,544
-171,706
-19% -$3.59M ﹤0.01% 1064
2024
Q4 		$22.7M Sell
916,250
-292,796
-24% -$8.31M ﹤0.01% 968
2024
Q3 		$34.5M Sell
1,209,046
-152,603
-11% -$4.5M ﹤0.01% 858
2024
Q2 		$35.9M Sell
1,361,649
-500,394
-27% -$14.2M ﹤0.01% 816
2024
Q1 		$60.2M Buy
1,862,043
+259,481
+16% +$9.47M 0.01% 678
2023
Q4 		$67.5M Buy
1,602,562
+872,520
+120% +$32.1M 0.01% 622
2023
Q3 		$28M Buy
730,042
+710,514
+3,638% +$16.1M ﹤0.01% 837
2023
Q2 		$371K Sell
19,528
-423,676
-96% -$7.9M ﹤0.01% 2276
2023
Q1 		$6.88M Buy
443,204
+167,205
+61% +$2.9M ﹤0.01% 1118
2022
Q4 		$4.9M Buy
+275,999
New +$3.48M ﹤0.01% 1196
2021
Q4 		– Sell
-22,680
Closed -$197K – 3013
2021
Q3 		$197K Buy
22,680
+5,077
+29% +$45.8K ﹤0.01% 2732
2021
Q2 		$186K Buy
17,603
+345
+2% +$4.82K ﹤0.01% 2745
2021
Q1 		$277K Sell
17,258
-272,730
-94% -$7.19M ﹤0.01% 2591
2020
Q4 		$13.4M Buy
289,988
+84,438
+41% +$3.9M ﹤0.01% 1306
2020
Q3 		$7.23M Buy
+205,550
New +$6.18M ﹤0.01% 1362

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates's IMVT Position: Q2 2026 in Review

T. Rowe Price Associates increased its Immunovant (IMVT) stake by 439% in Q2 2026, buying an estimated $45.4M and bringing the position to 1,829,210 shares worth $70.5M. The position accounts for 0.01% of the portfolio, ranked #787.

T. Rowe Price Associates first reported a position in IMVT in Q3 2020 and has held it in 20 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • T. Rowe Price Associates held 1,829,210 shares of Immunovant worth $70.5M as of Q2 2026.
  • T. Rowe Price Associates bought 1,489,603 Immunovant shares in Q2 2026, an estimated $45.4M.
  • Immunovant made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #787 holding.
  • T. Rowe Price Associates first reported a position in Immunovant in Q3 2020 and has held it in 20 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.